Transcode Therapeutics, Inc. — Director's Dealing 2024

Jun 18, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Transcode Therapeutics, Inc. (RNAZ)
CIK: 0001829635
Period of Report: 2024-06-14

Reporting Person: Marquet Magda (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-14	Stock Option (right to buy)	$1.20	A	70000	Acquired	2034-06-13	Common Stock (70000)	Direct

Footnotes

F1: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.